These findings clarified that Cav-1 could be considered as a new prognostic biomarker to predict resistance to radiotherapy in NSCLC.85 Recent studies have indicated that paraoxonase 2 (PON2), a lactonase/arylesterase with antioxidant properties, is significantly overexpressed in cancer tissues of NSCLC patients. This evidence concerns the gene CAV1 and cancer.